New study tracks PNH patients in china to understand rare blood disease
NCT ID NCT06154512
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study followed 724 people with paroxysmal nocturnal hemoglobinuria (PNH) in China to learn more about the disease and how patients respond to treatments. PNH is a rare blood disorder that can cause red blood cell breakdown, blood clots, and other serious problems. The study observed patients over time to track symptoms, lab results, and outcomes, including those treated with the drug eculizumab. The goal was to fill gaps in knowledge about PNH in Chinese patients and improve future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Hefei, Anhui, 230002, China
-
Research Site
Beijing, Beijing Municipality, 100000, China
-
Research Site
Beijing, Beijing Municipality, 100044, China
-
Research Site
Guangzhou, Guangdong, 510080, China
-
Research Site
Guangzhou, Guangdong, 510180, China
-
Research Site
Guangzhou, Guangdong, 510515, China
-
Research Site
Nanning, Guangxi, 530021, China
-
Research Site
Guiyang, Guizhou, 550004, China
-
Research Site
Shijiazhuang, Hebei, 050000, China
-
Research Site
Harbin, Heilongjiang, 150001, China
-
Research Site
Zhengzhou, Henan, 450003, China
-
Research Site
Zhengzhou, Henan, 450052, China
-
Research Site
Zhengzhou, Henan, 463599, China
-
Research Site
Wuhan, Hubei, 430000, China
-
Research Site
Wuhan, Hubei, 430030, China
-
Research Site
Changsha, Hunan, 410005, China
-
Research Site
Changsha, Hunan, 410008, China
-
Research Site
Nanjing, Jiangsu, 210029, China
-
Research Site
Nantong, Jiangsu, 226001, China
-
Research Site
Xuzhou, Jiangsu, 221002, China
-
Research Site
Nanchang, Jiangxi, 330006, China
-
Research Site
Nanchang, Jiangxi, 330008, China
-
Research Site
Changchun, Jilin, 130021, China
-
Research Site
Shenyang, Liaoning, 110001, China
-
Research Site
Jinan, Shandong, 250000, China
-
Research Site
Qingdao, Shandong, 266000, China
-
Research Site
Zibo, Shandong, 255090, China
-
Research Site
Linyi, Shangdong, 276034, China
-
Research Site
Shanghai, Shanghai Municipality, 200040, China
-
Research Site
Shanghai, Shanghai Municipality, 200336, China
-
Research Site
Taiyuan, Shanxi, 030000, China
-
Research Site
Xi’an, Shanxi, 710061, China
-
Research Site
Xi’an, Shanxi, 710068, China
-
Research Site
Chengdu, Sichuan, 610041, China
-
Research Site
Chengdu, Sichuan, 610072, China
-
Research Site
Tianjin, Tianjin Municipality, 300020, China
-
Research Site
Tianjin, Tianjin Municipality, 300052, China
-
Research Site
Tianjin, Tianjin Municipality, 300190, China
-
Research Site
Kunming, Yunnan, 650034, China
-
Research Site
Hangzhou, China
Conditions
Explore the condition pages connected to this study.